Glucotract, Inc. 完成人类第一次试验新的静脉放置血糖监测器,达到安全目标。 Glucotrack, Inc. completes first human trial of new vein-placed blood glucose monitor, meeting safety goals.

医疗技术公司Glucotract, Inc. 成功地完成了第一次人类试验,将新的连续血凝糖监测器(CBGM)放置在亚硅血管中。 Medical tech firm Glucotrack, Inc. successfully completed its first human trial for a new Continuous Blood Glucose Monitor (CBGM) placed in the subclavian vein. 该研究涉及6名糖尿病患者,在没有发生严重不良事件的情况下,达到了安全终点。 The study, involving six diabetes patients, met safety endpoints without serious adverse events. 虽然没有设计来测试准确性,但装置按预期运行。 Though not designed to test accuracy, the device performed as expected. Glucolatch计划进一步发展和商业化,旨在为糖尿病管理提供三年解决方案。 Glucotrack plans further development and commercialization, aiming to offer a three-year solution for diabetes management.